EpCAM Monoclonal Antibody (VU-1D9) | Invitrogen MA5-12153 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

EpCAM Monoclonal Antibody (VU-1D9)

catalog :

MA5-12153

quantity :

500 µL

price :

US 496.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

VU-1D9

reactivity :

human

application :

western blot, immunohistochemistry, immunocytochemistry, flow cytometry, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 15

Published Application/Species/Sample/Dilution	Reference
western blot; human; 1:1000	Kershaw S, Cummings J, Morris K, Tugwood J, Dive C. Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells. BMC Cancer. 2015;15:387 pubmed publisher
immunocytochemistry; human; 0.75 ug/ml	Shah P, Herrera Loeza S, Sims C, Yeh J, Allbritton N. Small sample sorting of primary adherent cells by automated micropallet imaging and release. Cytometry A. 2014;85:642-9 pubmed publisher
immunocytochemistry; human	Becker T, Caixeiro N, Lim S, Tognela A, Kienzle N, Scott K, et al. New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use. Int J Cancer. 2014;134:2523-33 pubmed publisher
western blot; human; 1:1000	Nasarre P, Gemmill R, Potiron V, Roche J, Lu X, Baron A, et al. Neuropilin-2 Is upregulated in lung cancer cells during TGF-?1-induced epithelial-mesenchymal transition. Cancer Res. 2013;73:7111-21 pubmed publisher
flow cytometry; human	Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick Silverman L, et al. Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential. PLoS ONE. 2013;8:e55145 pubmed publisher
immunohistochemistry; human; 1:200	Bauerschlag D, Bräutigam K, Moll R, Sehouli J, Mustea A, Salehin D, et al. Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary. J Cancer Res Clin Oncol. 2013;139:347-55 pubmed publisher
western blot; human	Horio M, Sato M, Takeyama Y, Elshazley M, Yamashita R, Hase T, et al. Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells. Ann Surg Oncol. 2012;19 Suppl 3:S634-45 pubmed publisher
immunohistochemistry; human	Kempers M, Kuiper R, Ockeloen C, Chappuis P, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12:49-55 pubmed publisher
immunohistochemistry; human	Ligtenberg M, Kuiper R, Chan T, Goossens M, Hebeda K, Voorendt M, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009;41:112-7 pubmed publisher
immunohistochemistry; human; 1:200	Meinhold Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso L, Orlowska Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24:1053-65 pubmed
	Sowamber R, Chehade R, Bitar M, Dodds L, Milea A, Slomovitz B, et al. CCAAT/enhancer binding protein delta (C/EBPδ) demonstrates a dichotomous role in tumour initiation and promotion of epithelial carcinoma. EBioMedicine. 2019;: pubmed publisher
	Nicolazzo C, Colangelo L, Corsi A, Carpino G, Gradilone A, Sonato C, et al. Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma. Anal Cell Pathol (Amst). 2018;2018:9718585 pubmed publisher
	Sansone P, Berishaj M, Rajasekhar V, Ceccarelli C, Chang Q, Strillacci A, et al. Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles. Cancer Res. 2017;77:1927-1941 pubmed publisher
	Quintanilla R, Asprer J, Sylakowski K, Lakshmipathy U. Kinetic Measurement and Real Time Visualization of Somatic Reprogramming. J Vis Exp. 2016;: pubmed publisher
	Schaner M, Ross D, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003;14:4376-86 pubmed

image

image 1 :

product information

Product Type :

Antibody

Product Name :

EpCAM Monoclonal Antibody (VU-1D9)

Catalog # :

MA5-12153

Quantity :

500 µL

Price :

US 496.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human

Applications :

Immunocytochemistry: 1:10-1:100, Immunohistochemistry (Paraffin): 1-2 µg/mL

Species :

Human

Clone :

VU-1D9

Isotype :

IgG1, kappa

Storage :

4° C

Description :

Ep-CAM (epithelial adhesion molecule, epithelial specific antigen, ESA) is a transmembrane glycoprotein expressed in the epithelium with a molecular weight of approximately 40 kDa, which functions as an epithelial cell adhesion molecule. Ep-CAM functions as a homotypic calcium-independent cell adhesion molecule, and has a direct impact on cell cycle, proliferation and metabolism of epithelial cells and fibroblasts due to its ability to rapidly induce the proto-oncogene c-myc and the cell cycle regulating genes cyclin A and E. Ep-CAM mediates Ca2+-independent homotypic interactions. Formation of Ep-CAM-mediated adhesions have a negative regulatory effect on adhesions mediated by classic cadherins, which may have strong effects on the differentiation and growth of epithelial cells. Ep-CAM overexpression was suggested to be associated with enhanced epithelial proliferation. Ep-CAM is highly expressed in human carcinomas, and is a marker for tumors of epithelial lineage. Ep-CAM is expressed on baso-lateral cell surface in most simple epithelia and many carcinoma types. Also, Ep-CAM reportedly distinguishes adenocarcinomas from pleural mesotheliomas.

Immunogen :

Small cell lung carcinoma cells

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:10-1:100, Immunohistochemistry (Paraffin): 1-2 µg/mL

Aliases :

adenocarcinoma-associated antigen; CD326; cell surface glycoprotein Trop-1; DIAR5; EGP; EGP-2; EGP314; EGP40; EPCAM; Ep-CAM; EpCAM1; epithelial cell adhesion molecule; Epithelial cell surface antigen; Epithelial glycoprotein; Epithelial glycoprotein 314; ESA; GA733-2; gp40; hEGP314; HNPCC8; human epithelial glycoprotein-2; KS 1/4 antigen; KS1/4; KSA; Ly74; lymphocyte antigen 74; M1S2; M4S1; major gastrointestinal tumor-associated protein GA733-2; mEGP314; membrane component, chromosome 4, surface marker (35kD glycoprotein); MIC18; MK-1; panepithelial glycoprotein 314; protein 289A; Protein D5.7A; Tacsd1; Tacstd1; TROP1; Trop-1 protein; Tumor-associated calcium signal transducer 1

more info or order :

Invitrogen product webpage